Book Value per Share: MannKind Corp (MNKD)

Graphic logo of MannKind Corporation (MNKD)

MannKind Corporation (MNKD) has developed a breakthrough insulin delivery method via inhalation, replacing injections with a powder form. The popularity of such therapies for diabetes and pulmonary hypertension is growing, driving an influx of new consumers. The business's environmental focus relies on inhaler recycling and emission reductions, with the current metric standing at -0.22. This price chart for the company on the GURU.Markets platform clearly illustrates the dynamics of these processes.

MannKind Corp (MNKD): Share Book Value from 07/04/2022 to 10/28/2026
Manufactured products of MannKind

Book value per share reflects the residual value of the issuer's net assets after all liabilities have been fully settled. Growth in this metric indicates business capitalization, whereas stagnation signals inefficient resource utilization. By analyzing the trend in book value per share, an investor determines the real intrinsic value of the security. For MannKind Corporation (MNKD), this trend confirms the effectiveness of production capacity optimization. Transparent licensing flows and competent management ensure a steady increase in the company's equity.

Competitors of MannKind Corporation (MNKD)

Haleon Group - Net Assets per Single Share|KVUE - Book Value per Share|Book Value per Share Verona Pharma plc|MENS (jyongbio.com) - Equity per Share|Net Assets per Single Share Ligand LGND|Share Book Value Amneal Pharmaceuticals, Inc.|Perrigo Company (PRGO) - Book Value per Share|Accounting Value of a Share Alvotech Biopharmaceuticals (ALVO)|Book Value per Share LQDA (Liquidia Corporation)|glpg.com - Book Value per Share|Net Assets per Single Share ANI Pharmaceuticals, Inc. (ANIP)|AMPH: Accounting Value of a Share|PCRX (Pacira) - Net Assets per Single Share|ARS Corp (SPRY) - Accounting Value per Share|TBPH (Theravance Biopharma) - Book Value per Share|Book Value per Share aquestive.com (AQST)|scPharmaceuticals Inc. (SCPH) - Accounting Value per Share|Accounting Value of a Share TECX (tectonictx.com)|TNXP: Net Assets per Single Share|SXTC - Net Asset Value per Share|Accounting Value per Share Eupraxia Pharma EPRX|BHST - Book Price of a Share|Book Value per Share eXoZymes EXOZ|Oramed Pharmaceuticals Inc. (ORMP) - Accounting Value of a Share|Book Value per Share ENTX (Entera Bio Ltd)|Net Asset Value per Share HYFT|ABVC BioPharma (ABVC) - Net Assets per Single Share|Accounting Value of a Share CPIX (cumberlandpharma.com)|Quantum BioPharma - Net Assets per Single Share|Accounting Value per Share FibroGen Inc FGEN|Telomir Pharma - Book Value per Share|RANI: Book Value per Share|Net Assets per Single Share synergychc.com|RLYB (Rallybio) - Equity per Share|Net Assets per Single Share Lexaria Bioscience Corp (LEXX)|Equity per Share PULM|Net Assets per Single Share PTHL|Book Value per Share aptorumgroup.com (APM)|Book Value per Share LYRA|Impact BioMedical, Inc. - Net Assets per Share|TNF Pharma (TNFA) - Net Assets per Single Share|YCBD - Equity per Share|Book Value per Share PainReform Limited|Equity per Share Altamira Therapeutics Ltd.|LIPO - Accounting Value per Share|Accounting Value of a Share optinose.com|Book Value per Share PIRS (Pieris Pharmaceuticals, Inc.)|Accounting Value per Share PROC (Procaps Group)|PTPI: Net Assets per Single Share|Qilian International Corp - Net Asset Value per Share|Net Assets per Single Share Acelyrin, Inc. (SLRN)|TFFP: Accounting Value of a Share